19:41 , Jun 2, 2017 |  BioCentury  |  Product Development

Ears wide open

Based on unmet need alone, hearing loss should have been every bit as attractive to investors and drug developers as ophthalmic diseases, which entered a renaissance in the mid-2000s resulting in a multibillion-dollar market for...
19:33 , Mar 31, 2017 |  BC Week In Review  |  Company News

Bionure Farma, Spiral Therapeutics deal

Bionure granted Spiral an option to acquire exclusive, worldwide rights to Bionure’s preclinical serum/glucocorticoid regulated kinase 2 (SGK2) agonists BN201 and BN119 to treat otolaryngology indications. Spiral plans to exercise the option by 3Q17. If...